Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Diluted Average) (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Shares Outstanding (Diluted Average) across 18 years of filings, most recently posting $1.2 billion for Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 1.73% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 1.73% YoY) and the FY2025 annual result came in at $1.2 billion, up 2.83% from the prior year.
• Shares Outstanding (Diluted Average) grew to $1.2 billion in Q1 2026, from $1.2 billion in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $1.2 billion in Q1 2026 and troughed at $1.1 billion in Q1 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) declined 0.18% — and 2025, when it rose 3.21%.
• Tracing TEVA's Shares Outstanding (Diluted Average) over 5 years: stood at $1.1 billion in 2022, then advanced by 0.81% to $1.1 billion in 2023, then climbed by 1.07% to $1.1 billion in 2024, then climbed by 2.83% to $1.2 billion in 2025, then increased by 1.38% to $1.2 billion in 2026.
• Business Quant data shows TEVA's Shares Outstanding (Diluted Average) at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.